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Background: In 2011 the Latin America Asthma Insight and Management (LA AIM) survey explored the realities of
living with asthma. We investigated perception, knowledge, and attitudes related to asthma among Latin American
asthma patients.
Methods: Asthma patients aged ≥12 years from four Latin American countries (Argentina, Brazil, Mexico, Venezuela)
and the Commonwealth of Puerto Rico responded to questions during face-to-face interviews. A sample size of
2,169 patients (approximately 400 patients/location) provided an accurate representation of asthma patients’
opinions. Questions probed respondents’ views on topics such as levels of asthma control, frequency and duration
of exacerbations, and current and recent use of asthma medications.
Results: A total of 2,169 adults or parents of children with asthma participated in the LA AIM survey. At least 20% of
respondents experienced symptoms every day or night or most days or nights. Although 60% reported their disease as
well or completely controlled, only 8% met guideline criteria for well-controlled asthma. 47% of respondents reported
episodes when their asthma symptoms were more frequent or severe than normal, and 44% reported seeking acute
care for asthma in the past year. Asthma patients in Latin America overestimated their degree of asthma control.
Conclusions: The LA AIM survey demonstrated the discrepancy between patient perception of asthma control and
guideline-mandated criteria. Additional education is required to teach patients that, by more closely following asthma
management strategies outlined by current guidelines more patients can achieve adequate asthma control.
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Asthma is a common disease across the world which af-
fects people in all age groups and exerts a significant bur-
den on patients and their families. Overall, asthma imposes
a high societal burden in terms of productivity loss as well
as resource utilization arising from poor asthma control.
In recent years, educational initiatives were implemented
to ensure that physicians know the latest evidence-based
asthma treatment guidelines and are able to incorporate
those guidelines in their clinical practices [1]. Evidence-
based guidelines provide objective strategies to achieve and* Correspondence: maspero@ciudad.com.ar
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reproduction in any medium, provided the ormeasure asthma control, although patients’ self-assessment
of their asthma severity and level of control are not ob-
jective. Although guidelines offer an algorithm to assess
disease control systematically and provide treatment rec-
ommendations that are easy to follow, patients worldwide
misjudge their level of asthma control despite the availa-
bility of guidelines with clear-cut strategies. Over- or
underestimating asthma control may result in ineffective
treatment-related behaviors, and recent survey data from
the United States suggest that patients may not be familiar
with basic concepts in asthma management [2-4].
In 2011 the Latin America Asthma Insight and Manage-
ment (LA AIM) survey was designed to ascertain the
realities of living with asthma, the disconnect between ex-
pectations in asthma management and patient experience,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ences across Latin America in patient perception of asthma
management practices and acceptable levels of asthma
control. Using results from this survey we are able to
evaluate the effectiveness of educational efforts to date.
This is important because the effectiveness of any treat-
ment strategy ultimately depends on actions taken by pa-
tients. Since patient perceptions drive treatment outcomes,
it is crucial to provide patients with sufficient evidence to
support informed decisions. The LA AIM survey explored
asthma-related patient perceptions, behaviors, and presen-
tation patterns, as well as recent trends in asthma manage-
ment in Latin America.Methods
The LA AIM survey was designed to explore and document
asthma-related patient perceptions, behaviors, and presen-
tation patterns, as well as recent trends in asthma manage-
ment. This survey was generally designed to follow the
methods used in the AIM surveys in the US, Europe and
Canada, and the Asia Pacific region. The LA AIM survey,
developed by Abt SRBI (New York, NY, USA), was con-
ducted in Argentina, Brazil, Mexico, Venezuela, and the
Commonwealth of Puerto Rico to provide data representa-
tive of the Latin American population. Participants were
randomly selected using national probability sampling. The
study was not subject to formal ethics approval or formal
consenting process in any country. The need for full consid-
eration, and written informed consent, was waived by the
Ethics Committee on Clinical Pharmacology at the CIDEA
Foundation in Argentina, the Ethics Committee of the Uni-
versidade Federal de São Paulo in Brazil, the Ethics Com-
mittee of the Instituto Nacional Enfermedades Respiritorias
Ismael Cosio Villegas in Mexico, the Cardio Pulmonary Re-
search Center in Puerto Rico, and the Bioethics Committee
for Research at Hospital de Clinicas Caracas in Venezuela.Table 1 Demographics and sample characteristics
Population adults/parents of
adolescents (12–17 yrs) with
asthma (physician diagnosed
and past-year medication or
asthma attacks)
Sampling frame screening of national
sample of households
Country Survey
organization
Households screened
Argentina TNS-Gallup 16,321
Brazil TNS 4,545
Mexico Buendia Y Laredo 24,495
Puerto
Rico
Interviewing
Resources Corp.
2,193
Venezuela StatMark 3,654
LA AIM TOTAL 51,208
AIM=Asthma insight and management.The data were not collected by doctors or other health
professionals. A survey organization based in each target
country collected the data for this study (Table 1). Profes-
sional interviewers read a standard text to introduce the
study and present the survey questions. For all countries
and institutions, adequate procedures were in place to en-
sure the privacy and confidentiality of participants. Patient
consent was explicitly obtained before the interview began,
and the respondent could refuse to cooperate at any point
in the interview. Identifiable personal information, includ-
ing names, were neither collected nor maintained in the
survey. The only unique identifier that existed at any time
during the survey process was the telephone number in
the sampling system during screening. That information
was not provided with the rest of the survey data by the
local data collection agency, and Abt SRBI received a to-
tally de-identified data set. The study population consisted
of adults age ≥18 years and parents of adolescents age 12–
17 years with asthma based on physician-diagnosis and
past-year medication use or asthma attacks. A total of
51,208 households were screened, yielding a sample of at
least 400 patients in each country/area. Survey data were
collected from each participant or their parent in a face-to-
face interview and lasting no more than 35 minutes. Data
were analyzed by individual country/area and for the entire
study population. The survey consisted of 53 questions
covering 5 asthma-related topics: 1) symptoms; 2) impact
of asthma on daily life; 3) perceptions of asthma control;
4) exacerbations; and 5) treatment and medication.
Questions on symptoms covered the frequency of day-
time and nighttime symptoms in the past 4 weeks,
symptom frequency during the worst month over the
past 12 months, and the frequency of sudden episodes
of severe symptoms. To assess the impact of asthma on
daily life, participants were asked about missed work or
school days due to asthma, activity limitations, and over-
all productivity when asthma was at its worst. RegardingInterview length mean:
35 minutes
Patients
Completed sample Female,
%
Mean
age, yrs
Mean age at
diagnosis, yrs
436 66 40 19
400 68 38 16
532 62 36 18
401 64 43 19
400 65 35 11
2,169 67 37 15
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to rate their/their child’s level of asthma control over the
past 4 weeks and the past year, and were asked to identify
criteria for well-controlled asthma. These perceived levels
of control were compared with asthma control classifi-
cation based on GINA guidelines.1 Participants were also
asked if they or their child had seen a doctor for exacerba-
tions, symptom worsening, or sudden severe episodes over
the past year. They were also asked if they or their child
had to go to the hospital for an overnight stay or went to
the emergency room for asthma, and how many times this
occurred over the past 12 months.
Regarding asthma treatment and medication, partici-
pants were asked about use of asthma controller medica-
tion and quick relief or rescue medication, and if their
doctor provided a written action plan for asthma man-
agement. Participants were also asked if they thought
long term control medicines should be taken every day,
if long term control medicines are not necessary when
asthma symptoms are not experienced regularly, and if
quick relief medicines can be used every day if needed.
All respondent data represent the percentage of pa-
tients who answered each respective survey question. No
inferential analyses were conducted, and comparisons
were for exploratory purposes only. For within-country
comparisons in the LA AIM survey, the maximum mar-
gin of error for 400 individual country/region samples
was ± 4.9% at the 95% confidence level. For across-
country comparisons, when comparing 2 independent
samples of 400, a difference of 6.9% is statistically signifi-
cant at the 95% confidence level. Overall survey compar-
isons for 2000 survey samples had a maximum margin
of error ±2.2% at the 95% confidence level.
Results
Persons with asthma who were interviewed in the LA
AIM survey were identified through the screening of
51,208 households, which found the household preva-
lence of asthma to be 3.4% in Argentina, 3.4% in
Mexico, 8.8% in Brazil, 16.6% in Venezuela, and 18.3%
in Puerto Rico. A total of 2,169 asthma patients were
interviewed in the LA AIM survey, with 436 from
Argentina, 400 from Brazil, 532 from Mexico, 401 from
Puerto Rico and 400 from Venezuela. The mean age of
respondents in the entire study population was 37 years,
and the majority (67%) of respondents were female. In
the entire study population, the mean age of respondents
when their asthma was first diagnosed was 15 years,
with median ages ranging from 7 years in Venezuela to
15 years in Argentina (Table 1).
Asthma burden
The proportion of respondents who experienced asthma
symptoms within the past 4 weeks was high. In the entirepopulation, 24% experienced daytime symptoms every day
or most days and 20% experienced nighttime symptoms
every night or most nights (Table 2). Respondents re-
ported shortness of breath during the day and awakening
at night by shortness of breath as the most bothersome
symptoms, in 24% and 22% of patients, respectively.
Nearly half (47%) of the entire study population reported
episodes in the past 12 months when asthma symptoms
were more frequent or severe than normal (Table 2). The
major triggers of asthma episodes in Latin America were
dust exposure and weather changes. The proportion of re-
spondents with asthma episodes was lowest in Mexico
(42%), and was significantly higher in Argentina (57%) and
Puerto Rico (61%) (Table 2). Slightly more than one-third
of respondents (37%) reported that sudden severe episodes
had a greater impact than day-to-day symptoms on their
quality of life.
The majority (59%) of respondents reported ever having
an asthma episode in which they or their children had to
go to the hospital for an overnight stay, and 11% reported
ever having been admitted to an intensive care unit for an
asthma episode. Survey questions also probed respon-
dents’ views on the frequency and duration of exacerba-
tions in the past year. Respondents were asked if they or
their children went to the hospital for an overnight stay
for asthma in the past 12 months, and if asthma caused
any unscheduled urgent or emergency visits to a doctor’s
office, hospital, clinic, or somewhere else in the past 12
months. In the entire population, 23% reported hos-
pitalizations and 44% reported unscheduled urgent or
emergency visits in the past 12 months (Figure 1). The
proportion of respondents who went to the hospital for an
overnight stay was significantly higher in Brazil (27%) than
it was in the other LA countries/regions (14−20%). The
proportion of unscheduled urgent or emergency visits was
significantly higher in Brazil (47%) and Puerto Rico (57%)
than it was in Mexico and Venezuela (37% each).
In the entire population, 40% of respondents reported
that they missed work or school due to asthma over the
past year, with a median of 3 days lost due to asthma. In
addition, about half of respondents reported asthma-
related activity limitations. The majority of respondents
(70%) said asthma sometimes or often made them feel
tired or fatigued, and 33% said asthma sometimes or
often made them fearful. Overall, 39% of respondents
thought their life was ever in danger during an asthma
episode (Table 2).
Controller medication use and perception of control
LA AIM survey respondents’ answers to questions about
controller medication use show disparities in patients’
and/or doctor’s understanding of what it is proposed by
the guidelines for recommended therapy and their atti-
tudes about the use of control medication as well as
Table 2 Responses to selected survey questions
Question Latin America
(n=2,169)
Argentina
(n=436)
Brazil
(n=400)
Mexico
(n=532)
Puerto Rico
(n=401)
Venezuela
(n=400)
Daytime symptom frequency, %
Every day/most days 24 35 27 12 34 18
1−2 days/week 22 25 20 20 15 29
1−2 times/month 11 8 10 18 7 11
No daytime symptoms 44 32 44 50 43 42
Nighttime symptom frequency, %
Every night/most nights 20 28 24 9 26 14
1−2 nights/week 16 20 16 16 15 18
1−2 times/month 10 8 11 12 5 10
No nighttime symptoms 53 45 50 62 53 58
Subjects with episodes in the past 12 months with asthma
symptoms more frequent or more severe than normal, %
47 57 46 42 61 48
Median number of episodes 2 3 2 3 3 3
Subjects who agreed with the following statements, %
Long-term control medicines should be taken every day 41 61 41 48 61 26
Long-term control medicines are not necessary when asthma
symptoms are not experienced regularly
65 55 67 54 59 72
Quick relief medications can be used every day if needed 61 68 58 56 84 71
Subjects reporting ≥1 week of interrupted asthma controller
medicine use, %
<2 weeks 26 32 26 29 15 21
3−4 weeks 9 10 8 14 9 10
≥1 month 61 49 52 52 71 65
GINA 2009 asthma control levels
Well controlled, % 8 5 9 9 8 3
Partly controlled, % 57 48 57 56 59 65
Uncontrolled, % 35 57 34 35 33 32
GINA=Global initiative for asthma.
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ported that their doctor had developed a written action
plan for asthma treatment, and 50% of these respon-
dents (n=919) said their doctor reviewed the plan at
every visit. Although 34% of respondents said they had
heard of a peak flow meter, only 12% of these respon-
dents actually had a peak flow meter. In the entire LA
population, 41% of respondents agreed somewhat or
strongly agreed with the statement that long-term con-
trol medication should be taken every day. However,
65% of patients felt that long-term use of asthma control
medication was unnecessary when symptoms were not
present and 61% overall felt that everyday use of rescue
inhalers was acceptable (Table 2). Less than half (45%) of
respondents reported use of controller medication over
the past 4 weeks, whereas a majority (63%) of respon-
dents reported use of quick relief medication over the
past 4 weeks. In addition, 60% of respondents said
they worry about using inhaled corticosteroids. Theproportion of respondents reporting use of controller
medication was highest in Puerto Rico (60%) and lowest
in Venezuela (35%).
For methods of administering controller medication,
29% of respondents in the entire population reported the
use of a pill, 20% reported the use of a nebulizer, and 55%
reported the use of an inhaler (Table 2). Proportions of re-
spondents reporting inhaler use for controller medication
ranged from 42% in Brazil to 82% in Mexico. Among re-
spondents who reported they or their child had stopped
taking controller medication for a week or longer, 61% re-
ported an interruption of ≥1 month (Table 2).
The survey found that asthma patients in Latin America
overestimated their degree of asthma control. When re-
spondents were asked how well they would say their or
their child’s asthma has been controlled in the past 4
weeks, a majority (60%) of respondents reported their
disease as completely controlled or well controlled. How-
ever, only 8% met the GINA guideline criteria for well-
23%
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Figure 1 Patient-reported acute treatment for asthma in past year question asked: (Have you/Has your child) been hospitalized for
asthma in the past 12 months?. Has (your/your child’s) asthma caused any unscheduled urgent or emergency visits to a doctor’s office,
hospital, clinic, or somewhere else in the past 12 months?
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respondents who perceived their asthma as being well
controlled. Based on GINA control classification accord-
ing to symptom frequency, activity limitation, and use of
reliever treatment, 35% of LA AIM survey respondents
would be considered to have uncontrolled asthma
(Table 2).
In addition to overestimating their levels of asthma
control, respondents had low expectations regarding the27% 
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Figure 2 Asthma control classification by perceived control levels.benefits of successful asthma management. About half
of respondents (44−51%) would consider asthma to be
well controlled if they or their child had only 2 urgent
doctor visits, only 1 emergency room visit, or only 3 or
4 asthma attacks per year (Table 2).
Discussion
Our findings from LA AIM reveal three relevant issues:
1) there is a high degree of agreement between countries1% 
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exists, with respect to the overall disease burden im-
posed by asthma, including asthma control, exacerbation
rates, disease management approaches, and resource
utilization; 2) asthma in LA, according to GINA, [1] is
far from the standards of being well controlled; and 3)
the burden of asthma identified in previous surveys of
the region [5-9] continue to exist.
With a few exceptions the LA AIM found that patients
with asthma from different countries responded with a
very similar pattern of perceptions, behaviors and trends
in asthma management. Most important is the fact that
56% and 47% of LA patients did report having daytime
and nighttime symptoms, respectively, suggesting that
they are used to living like this and misinterpret the con-
cept of well controlled asthma. In this sense, although 60%
of adults and adolescents with asthma in Latin America
say they have been well or completely controlled in the
past 4 weeks, only 8% would be classified as having con-
trolled asthma according to GINA, whereas 57% would be
classified as partly controlled, and 35% as uncontrolled.
Similar results were observed in the US AIM study [4].
Almost half (47%) of adults and adolescents with asthma
in Latin America reported episodes in the past year when
their asthma symptoms are more frequent or severe than
normal. Also, almost half (46%) of patients in Latin
America report seeking acute care for asthma in the past
12 months, including being hospitalized for an overnight
stay, emergency room visits, and other emergency medical
care visits. Almost two-fifths of asthma patients in Latin
America (39%) have felt their life was ever in danger dur-
ing an acute episode. This may involve events such as an
asthma attack followed by hospitalization for an overnight
stay, admission to an intensive care unit, or loss of con-
sciousness. Three out of five patients in Latin America ex-
press worry about using inhaled steroids (60%), as well as
oral corticosteroids (61%). Fear of inhaled steroids directly
promotes nonadherence to daily controller medication
therapy, which can lead to episodes of asthma worsening
with increased use of oral steroid bursts and emergency
care or hospitalization for an overnight stay.
Patient expectations of asthma management are low;
about half of patients consider their asthma well con-
trolled if they have 2 urgent doctor visits per year, and
about half of patients consider their asthma well con-
trolled if they have 3 or 4 exacerbations per year. Reported
patterns of medication use include infrequent utilization
of controller therapy, interruptions in controller therapy,
and excessive reliance on quick-relief agents. The accept-
ance of a certain degree of symptoms or exacerbations as
normal obviously leads to overestimation of control status
by patients. Many respondents did not have a clear under-
standing of adequate asthma control or how to measure
control (e.g., use of a peak-flow meter). Overall, asthmaimposes a high societal burden in terms of productivity
loss as well as resource utilization arising from poor
asthma control.
In 2003, the Asthma Insights and Reality in Latin Amer-
ica (AIRLA) survey assessed perception, knowledge, and
attitudes related to asthma.5 Despite differences in their
methodologies, the LA AIM and AIRLA surveys identified
similar proportions of patients who experienced asthma
symptoms over the past 4 weeks, and of patients who
overestimated their asthma control based on GINA guide-
lines. This reveals ongoing discrepancies between patient
perceptions of asthma control and guideline-defined con-
trol in LA surveys. Similar differences between patient
perceptions of control and guideline-defined control were
also observed in the US-AIM survey, [4] and also in the
Asia-Pacific AIM survey conducted in 8 countries and
Hong Kong [10].
Conclusions
Based on patients’ self-reports of frequency and severity of
symptoms and their perceptions of control, findings from
this survey indicate that a large proportion of asthma pa-
tients in Latin America overestimate their levels of asthma
control. The burden of asthma remains significantly high,
and patients’ perception of control is not in agreement
with actual level of asthma severity and symptoms. In spite
of treatment guidelines, use of controller medication re-
mains insufficient. It is important to interrupt patients’ ac-
ceptance of asthma burden, and recognize that persistent
burden exists in spite of the availability of effective therap-
ies. Actions are required to facilitate the assessment of
asthma burden and effectiveness of asthma management,
and to reverse patient-exhibited lack of conviction on
treatment recommendations and suggested goals. A need
exists in Latin America to implement educational efforts
for physicians and patients on the management and con-
trol of asthma. Given that effective controller medications
and guidelines for their proper use already exist, an im-
portant public health goal should be to promote their ap-
plication in order to reduce the individual and societal
burden of asthma.
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